Trial intelligence / Profile preview

AX-158 in mild to moderate plaque psoriasis

NCT05725057Phase 2Completed

Sponsor
Artax Biopharma
Start
Nov 2023
Primary completion
Sep 2024
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of AX-158 in plaque psoriasis, sponsored by Artax Biopharma. Started Nov 2023; status: completed.

02

Drugs

AX-158
03

Conditions

plaque psoriasis

Beyond the preview

Go deeper on NCT05725057.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05725057.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call